Strategies of engineering nanomedicines for tumor retention

Xindi Qian; Xiaoxuan Xu; Yao Wu; Jiaoying Wang; Jie Li; Shuo Chen; Jingyuan Wen; Yaping Li; Zhiwen Zhang

doi:10.1016/j.jconrel.2022.04.006

Strategies of engineering nanomedicines for tumor retention

J Control Release. 2022 Jun:346:193-211. doi: 10.1016/j.jconrel.2022.04.006. Epub 2022 Apr 23.

Authors

Xindi Qian¹, Xiaoxuan Xu¹, Yao Wu², Jiaoying Wang³, Jie Li³, Shuo Chen⁴, Jingyuan Wen⁴, Yaping Li⁵, Zhiwen Zhang⁶

Affiliations

¹ State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China.
² State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Pharmacy, Fudan University, Shanghai 201203, China.
³ State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
⁴ School of Pharmacy, the University of Auckland, Auckland 1142, New Zealand.
⁵ State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Pharmacy, Fudan University, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China. Electronic address: ypli@simm.ac.cn.
⁶ State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; School of Pharmacy, Fudan University, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address: zhangzhiwen@fudan.edu.cn.

PMID: 35447297
DOI: 10.1016/j.jconrel.2022.04.006

Abstract

The retention of therapeutic agents in solid tumors at sufficient concentration and duration is crucial for their antitumor effects. Given the important contribution of nanomedicines to oncology, we herein summarized two major strategies of nanomedicines for tumor retention, such as transformation- and interactions-mediated strategies. The transformation-mediated retention strategy was achieved by enlarging particle size of nanomedicines or modulating the morphology into fibrous structures, while the interactions-mediated retention strategy was accomplished by modulating nanomedicines to promote their interactions with versatile cells or components in tumors. Moreover, we provide some considerations and perspectives of tumor-retaining nanomedicines for effective cancer therapy.

Keywords: Drug delivery; Morphology changes; Nanomedicines; Size-enlargement; Tumor retention.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / therapeutic use
Drug Delivery Systems
Humans
Nanomedicine
Nanoparticles* / chemistry
Neoplasms* / drug therapy
Neoplasms* / pathology

Substances

Antineoplastic Agents